Oleclumab

Oleclumab (INN;[1] development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.[2]

Oleclumab
Monoclonal antibody
Type?
SourceHuman
Target5'-nucleotidase NT5E
Clinical data
Other namesMEDI9447
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6348H9826N1710O1998S40
Molar mass143350.81 g·mol−1

This drug was developed by MedImmune/AstraZeneca.[3]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.